308 related articles for article (PubMed ID: 11914912)
1. P-glycoprotein inhibition by the multidrug resistance-reversing agent MS-209 enhances bioavailability and antitumor efficacy of orally administered paclitaxel.
Kimura Y; Aoki J; Kohno M; Ooka H; Tsuruo T; Nakanishi O
Cancer Chemother Pharmacol; 2002 Apr; 49(4):322-8. PubMed ID: 11914912
[TBL] [Abstract][Full Text] [Related]
2. Enhanced oral bioavailability and anti-tumour effect of paclitaxel by 20(s)-ginsenoside Rg3 in vivo.
Yang LQ; Wang B; Gan H; Fu ST; Zhu XX; Wu ZN; Zhan DW; Gu RL; Dou GF; Meng ZY
Biopharm Drug Dispos; 2012 Nov; 33(8):425-36. PubMed ID: 22898996
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of novel P-glycoprotein inhibitors to increase the oral uptake of paclitaxel in mice.
Bardelmeijer HA; Ouwehand M; Beijnen JH; Schellens JH; van Tellingen O
Invest New Drugs; 2004 Aug; 22(3):219-29. PubMed ID: 15122069
[TBL] [Abstract][Full Text] [Related]
4. Enhanced oral paclitaxel absorption with vitamin E-TPGS: effect on solubility and permeability in vitro, in situ and in vivo.
Varma MV; Panchagnula R
Eur J Pharm Sci; 2005; 25(4-5):445-53. PubMed ID: 15890503
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576.
Mistry P; Stewart AJ; Dangerfield W; Okiji S; Liddle C; Bootle D; Plumb JA; Templeton D; Charlton P
Cancer Res; 2001 Jan; 61(2):749-58. PubMed ID: 11212278
[TBL] [Abstract][Full Text] [Related]
6. Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreated with cyclosporin A.
van Asperen J; van Tellingen O; van der Valk MA; Rozenhart M; Beijnen JH
Clin Cancer Res; 1998 Oct; 4(10):2293-7. PubMed ID: 9796957
[TBL] [Abstract][Full Text] [Related]
7. Effect of genistein on the pharmacokinetics of paclitaxel administered orally or intravenously in rats.
Li X; Choi JS
Int J Pharm; 2007 Jun; 337(1-2):188-93. PubMed ID: 17267149
[TBL] [Abstract][Full Text] [Related]
8. Effects of silibinin, inhibitor of CYP3A4 and P-glycoprotein in vitro, on the pharmacokinetics of paclitaxel after oral and intravenous administration in rats.
Lee CK; Choi JS
Pharmacology; 2010; 85(6):350-6. PubMed ID: 20523105
[TBL] [Abstract][Full Text] [Related]
9. Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein.
Bardelmeijer HA; Beijnen JH; Brouwer KR; Rosing H; Nooijen WJ; Schellens JH; van Tellingen O
Clin Cancer Res; 2000 Nov; 6(11):4416-21. PubMed ID: 11106262
[TBL] [Abstract][Full Text] [Related]
10. Effects of silymarin and formulation on the oral bioavailability of paclitaxel in rats.
Park JH; Park JH; Hur HJ; Woo JS; Lee HJ
Eur J Pharm Sci; 2012 Feb; 45(3):296-301. PubMed ID: 22172604
[TBL] [Abstract][Full Text] [Related]
11. Effects of lipid vehicle and P-glycoprotein inhibition on the mesenteric lymphatic transport of paclitaxel in unconscious, lymph duct-cannulated rats.
Cai Q; Deng X; Li Z; An D; Shen T; Zhong M
Drug Deliv; 2016; 23(1):147-53. PubMed ID: 24786483
[TBL] [Abstract][Full Text] [Related]
12. The mechanism of enhancement on oral absorption of paclitaxel by N-octyl-O-sulfate chitosan micelles.
Mo R; Jin X; Li N; Ju C; Sun M; Zhang C; Ping Q
Biomaterials; 2011 Jul; 32(20):4609-20. PubMed ID: 21440934
[TBL] [Abstract][Full Text] [Related]
13. The influence of enaminones on the transport and oral bioavailability of P-glycoprotein substrate therapeutic agents.
Salama NN; Scott KR; Eddington ND
Int J Pharm; 2004 Apr; 273(1-2):135-47. PubMed ID: 15010138
[TBL] [Abstract][Full Text] [Related]
14. Altered oral bioavailability and pharmacokinetics of P-glycoprotein substrates by coadministration of biochanin A.
Peng SX; Ritchie DM; Cousineau M; Danser E; Dewire R; Floden J
J Pharm Sci; 2006 Sep; 95(9):1984-93. PubMed ID: 16850393
[TBL] [Abstract][Full Text] [Related]
15. Coadministration of oral cyclosporin A enables oral therapy with paclitaxel.
Meerum Terwogt JM; Malingré MM; Beijnen JH; ten Bokkel Huinink WW; Rosing H; Koopman FJ; van Tellingen O; Swart M; Schellens JH
Clin Cancer Res; 1999 Nov; 5(11):3379-84. PubMed ID: 10589748
[TBL] [Abstract][Full Text] [Related]
16. Altered pharmacokinetics of paclitaxel by the concomitant use of morin in rats.
Choi BC; Choi JS; Han HK
Int J Pharm; 2006 Oct; 323(1-2):81-5. PubMed ID: 16806758
[TBL] [Abstract][Full Text] [Related]
17. Enhanced oral bioavailability of paclitaxel by coadministration of the P-glycoprotein inhibitor KR30031.
Woo JS; Lee CH; Shim CK; Hwang SJ
Pharm Res; 2003 Jan; 20(1):24-30. PubMed ID: 12608532
[TBL] [Abstract][Full Text] [Related]
18. Comparative pharmacokinetics of paclitaxel after oral administration of Taxus yunnanensis extract and pure paclitaxel to rats.
Jin J; Cai D; Bi H; Zhong G; Zeng H; Gu L; Huang Z; Huang M
Fitoterapia; 2013 Oct; 90():1-9. PubMed ID: 23811429
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of oral bioavailability of paclitaxel after oral administration of Schisandrol B in rats.
Jin J; Bi H; Hu J; Zhong G; Zhao L; Huang Z; Huang M
Biopharm Drug Dispos; 2010 May; 31(4):264-8. PubMed ID: 20437465
[TBL] [Abstract][Full Text] [Related]
20. Effect of coumarin derivative-mediated inhibition of P-glycoprotein on oral bioavailability and therapeutic efficacy of paclitaxel.
Lee K; Chae SW; Xia Y; Kim NH; Kim HJ; Rhie S; Lee HJ
Eur J Pharmacol; 2014 Jan; 723():381-8. PubMed ID: 24252806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]